X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 16, 2021
Details:
Under the terms of the agreement, Italfarmaco gains the exclusive rights to commercialize Rivastigmine MD in Germany, Italy, Portugal and Greece. Italfarmaco will also have a preferred right to market Rivastigmine MD in Chile and Vietnam.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2021
Details:
According to the agreement, Luye Pharma has granted Towa the exclusive rights to develop and commercialize Rivastigmine MD in Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
It is the first transdermal patch product approved for marketing under China CDE’s quality and efficacy consistency evaluation. Rivastigmine Transdermal Patch works by delivering medication through the epidermis and dermis to the dermal layer.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
